<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d190" origId="Clofibrate"><sentence id="DrugDDI.d190.s0" origId="s0" text="Caution should be exercised when anticoagulants are given in conjunction with Atromid-S."><entity id="DrugDDI.d190.s0.e0" origId="s0.p5" charOffset="33-47" type="drug" text="anticoagulants"/><entity id="DrugDDI.d190.s0.e1" origId="s0.p8" charOffset="78-88" type="drug" text="Atromid-S"/><pair id="DrugDDI.d190.s0.p0" e1="DrugDDI.d190.s0.e0" e2="DrugDDI.d190.s0.e1" interaction="true"/></sentence><sentence id="DrugDDI.d190.s1" origId="s1" text="Usually, the dosage of the anticoagulant should be reduced by one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications."><entity id="DrugDDI.d190.s1.e0" origId="s1.p11" charOffset="27-40" type="drug" text="anticoagulant"/><entity id="DrugDDI.d190.s1.e1" origId="s1.p24" charOffset="163-170" type="drug" text="prevent"/><pair id="DrugDDI.d190.s1.p0" e1="DrugDDI.d190.s1.e0" e2="DrugDDI.d190.s1.e1" interaction="false"/></sentence><sentence id="DrugDDI.d190.s2" origId="s2" text="Frequent prothrombin determinations are advisable until it has been determined definitely that the prothrombin level has been stabilized."><entity id="DrugDDI.d190.s2.e0" origId="s2.p26" charOffset="9-20" type="drug" text="prothrombin"/></sentence><sentence id="DrugDDI.d190.s3" origId="s3" text="Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites."><entity id="DrugDDI.d190.s3.e0" origId="s3.p39" charOffset="0-10" type="drug" text="Atromid-S"/><entity id="DrugDDI.d190.s3.e1" origId="s3.p42" charOffset="30-35" type="drug" text="drugs"/><entity id="DrugDDI.d190.s3.e2" origId="s3.p43" charOffset="44-53" type="drug" text="phenytoin"/><entity id="DrugDDI.d190.s3.e3" origId="s3.p45" charOffset="57-68" type="drug" text="tolbutamide"/><pair id="DrugDDI.d190.s3.p0" e1="DrugDDI.d190.s3.e0" e2="DrugDDI.d190.s3.e1" interaction="true"/><pair id="DrugDDI.d190.s3.p1" e1="DrugDDI.d190.s3.e0" e2="DrugDDI.d190.s3.e2" interaction="false"/><pair id="DrugDDI.d190.s3.p2" e1="DrugDDI.d190.s3.e0" e2="DrugDDI.d190.s3.e3" interaction="true"/><pair id="DrugDDI.d190.s3.p3" e1="DrugDDI.d190.s3.e1" e2="DrugDDI.d190.s3.e2" interaction="false"/><pair id="DrugDDI.d190.s3.p4" e1="DrugDDI.d190.s3.e1" e2="DrugDDI.d190.s3.e3" interaction="false"/><pair id="DrugDDI.d190.s3.p5" e1="DrugDDI.d190.s3.e2" e2="DrugDDI.d190.s3.e3" interaction="false"/></sentence><sentence id="DrugDDI.d190.s4" origId="s4" text="Caution should be exercised when treating patients with either of these drugs or other highly protein-bound drugs and Atromid-S."><entity id="DrugDDI.d190.s4.e0" origId="s4.p54" charOffset="72-77" type="drug" text="drugs"/><entity id="DrugDDI.d190.s4.e1" origId="s4.p58" charOffset="118-128" type="drug" text="Atromid-S"/><pair id="DrugDDI.d190.s4.p0" e1="DrugDDI.d190.s4.e0" e2="DrugDDI.d190.s4.e1" interaction="false"/></sentence><sentence id="DrugDDI.d190.s5" origId="s5" text="The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently."><entity id="DrugDDI.d190.s5.e0" origId="s5.p59" charOffset="4-23" type="drug" text="hypoglycemic effect"/><entity id="DrugDDI.d190.s5.e1" origId="s5.p60" charOffset="27-38" type="drug" text="tolbutamide"/><entity id="DrugDDI.d190.s5.e2" origId="s5.p67" charOffset="74-84" type="drug" text="Atromid-S"/><pair id="DrugDDI.d190.s5.p0" e1="DrugDDI.d190.s5.e0" e2="DrugDDI.d190.s5.e1" interaction="false"/><pair id="DrugDDI.d190.s5.p1" e1="DrugDDI.d190.s5.e0" e2="DrugDDI.d190.s5.e2" interaction="false"/><pair id="DrugDDI.d190.s5.p2" e1="DrugDDI.d190.s5.e1" e2="DrugDDI.d190.s5.e2" interaction="true"/></sentence><sentence id="DrugDDI.d190.s6" origId="s6" text="Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months."><entity id="DrugDDI.d190.s6.e0" origId="s6.p79" charOffset="113-121" type="drug" text="fibrate"/><entity id="DrugDDI.d190.s6.e1" origId="s6.p81" charOffset="125-135" type="drug" text="lovastatin"/><pair id="DrugDDI.d190.s6.p0" e1="DrugDDI.d190.s6.e0" e2="DrugDDI.d190.s6.e1" interaction="false"/></sentence><sentence id="DrugDDI.d190.s7" origId="s7" text="For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure."><entity id="DrugDDI.d190.s7.e0" origId="s7.p99" charOffset="109-113" type="drug" text="drug"/><entity id="DrugDDI.d190.s7.e1" origId="s7.p102" charOffset="168-178" type="drug" text="lovastatin"/><entity id="DrugDDI.d190.s7.e2" origId="s7.p104" charOffset="185-193" type="drug" text="fibrate"/><pair id="DrugDDI.d190.s7.p0" e1="DrugDDI.d190.s7.e0" e2="DrugDDI.d190.s7.e1" interaction="false"/><pair id="DrugDDI.d190.s7.p1" e1="DrugDDI.d190.s7.e0" e2="DrugDDI.d190.s7.e2" interaction="false"/><pair id="DrugDDI.d190.s7.p2" e1="DrugDDI.d190.s7.e1" e2="DrugDDI.d190.s7.e2" interaction="true"/></sentence><sentence id="DrugDDI.d190.s8" origId="s8" text="While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate."><entity id="DrugDDI.d190.s8.e0" origId="s8.p120" charOffset="59-67" type="drug" text="fibrates"/><entity id="DrugDDI.d190.s8.e1" origId="s8.p121" charOffset="79-91" type="drug" text="gemfibrozil"/><entity id="DrugDDI.d190.s8.e2" origId="s8.p130" charOffset="170-178" type="drug" text="fibrates"/><entity id="DrugDDI.d190.s8.e3" origId="s8.p132" charOffset="196-206" type="drug" text="clofibrate"/><pair id="DrugDDI.d190.s8.p0" e1="DrugDDI.d190.s8.e0" e2="DrugDDI.d190.s8.e1" interaction="false"/><pair id="DrugDDI.d190.s8.p1" e1="DrugDDI.d190.s8.e0" e2="DrugDDI.d190.s8.e2" interaction="false"/><pair id="DrugDDI.d190.s8.p2" e1="DrugDDI.d190.s8.e0" e2="DrugDDI.d190.s8.e3" interaction="false"/><pair id="DrugDDI.d190.s8.p3" e1="DrugDDI.d190.s8.e1" e2="DrugDDI.d190.s8.e2" interaction="false"/><pair id="DrugDDI.d190.s8.p4" e1="DrugDDI.d190.s8.e1" e2="DrugDDI.d190.s8.e3" interaction="false"/><pair id="DrugDDI.d190.s8.p5" e1="DrugDDI.d190.s8.e2" e2="DrugDDI.d190.s8.e3" interaction="false"/></sentence><sentence id="DrugDDI.d190.s9" origId="s9" text="Therefore, the combined use of lovastatin with fibrates should generally be avoided."><entity id="DrugDDI.d190.s9.e0" origId="s9.p135" charOffset="31-41" type="drug" text="lovastatin"/><entity id="DrugDDI.d190.s9.e1" origId="s9.p136" charOffset="47-55" type="drug" text="fibrates"/><pair id="DrugDDI.d190.s9.p0" e1="DrugDDI.d190.s9.e0" e2="DrugDDI.d190.s9.e1" interaction="true"/></sentence></document>